For research purposes only. Not for human consumption.
Description:
Tirzepatide is a synthetic, 39-amino-acid peptide engineered to activate both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Its structure includes amino-acid substitutions and a lipid-containing side chain designed to increase protein binding and extend pharmacokinetic persistence.
The compound is studied in relation to incretin-receptor pharmacology, glucose-dependent cellular signalling and metabolic regulation. Tirzepatide is the active pharmaceutical ingredient in certain TGA-registered prescription medicines; however, this does not confer approval upon independently manufactured or unregistered tirzepatide products.
Tirzepatide is a prescription-only medicine in Australia and must not be advertised to the general public or supplied outside lawful regulatory and clinical pathways.
